Medicine and Dentistry
Rhabdomyosarcoma
100%
Pediatrics
62%
Soft Tissue Sarcoma
52%
Neoplasm
33%
Adolescence
28%
Chemotherapy
24%
Radiation Therapy
23%
Overall Survival
21%
Event Free Survival
17%
Childhood Cancer
16%
Disease
13%
Neck
12%
Malignant Neoplasm
12%
Ewing Sarcoma
10%
Pediatrics Patient
9%
Lymph Node
8%
Embryonal Rhabdomyosarcoma
8%
Metastatic Carcinoma
8%
Oncology
7%
Primary Tumor
6%
Solid Malignant Neoplasm
6%
Risk Stratification
6%
Connective Tissue Cancer
6%
Quality of Life
6%
Paediatric Radiology
6%
Systematic Review
6%
Local Therapy
5%
Positron Emission Tomography-Computed Tomography
5%
Fluorodeoxyglucose F 18
5%
Ganglioneuroblastoma
5%
Biological Marker
5%
Adverse Event
5%
Cancer Susceptibility
5%
Liquid Biopsy
5%
Cohort Analysis
5%
Lung
5%
Clinical Trial
5%
Vincristine
5%
High Dose Chemotherapy
5%
Hematopoietic Cell
5%
Lung Nodule
5%
Cell Transplantation
5%
Keyphrases
Rhabdomyosarcoma
79%
Pediatric Soft Tissue Sarcomas
49%
Overall Survival
25%
Event-free Survival
24%
Radiotherapy
22%
Children with Cancer
19%
Older Adults
18%
Tumor
16%
Chemotherapy
15%
Head-and-neck
15%
Pediatric
15%
Ewing Sarcoma
12%
Confidence Interval
12%
Working Diagnosis
12%
Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
11%
Survivors
11%
Pediatric Patients
11%
Pediatric Oncology
10%
Preadolescent children
10%
Childhood Cancer
10%
Soft Tissue Sarcoma
9%
Metastatic Rhabdomyosarcoma
9%
Health-related Quality of Life
9%
Embryonal Rhabdomyosarcoma
8%
Nodal Involvement
8%
Craniofacial
7%
Cancer Predisposition Syndrome
7%
EPS-SG
7%
Extremity Rhabdomyosarcoma
7%
Risk Stratification
6%
Pediatric Radiology
6%
Local Treatment
5%
5-year Survival
5%
Young Cancer Patients
5%
Europe
5%
Childhood Cancer Patients
5%
Liquid Biopsy
5%
Netherlands
5%
Forkhead Box O1 (FOXO1)
5%
Patient Journey
5%
High-dose Chemotherapy
5%
18F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography
5%
European Guidelines
5%
Pediatric Tumors
5%
Randomized Phase II Trial
5%
Indeterminate Pulmonary Nodules
5%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
5%
Dutch
5%